Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
Tweet
Share
E-mailGet Alerts CLDI Hot Sheet
Join SI Premium – FREE
Calidi Biotherapeutics (NYSE: CLDI) reported Q2 EPS of ($2.94).
For earnings history and earnings-related data on Calidi Biotherapeutics (CLDI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Starbucks (SBUX) call put ratio 1.2 calls to 1 put amid headlines
- Humana (HUM) call put ratio 1 call to 1.2 puts into CMS release of latest Star ratings
- AT&T (T) call put ratio 8.8 calls to 1 put into SpaceX (SPCX) announcement of spectrum license
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
